ERBB2 and carcinoma: Using microarray-based gene expression data from three independent cohorts of 766 node-negative breast cancer patients, Siggelkow et al. demonstrated that patients harboring high Aurora-A expression had a shorter metastasis-free survival in the molecular subtype estrogen receptor-positive (ER+)/HER2− carcinomas, but not in ER−/HER2− or HER2+ carcinomas (73).